News from REMEDY

What happens when patients not only participate in research, but actually help shape it? In this podcast, hosted by PROMINET, the spotlight is on user participation in research. The goal is simple but ambitious: to make research more relevant to those it concerns most.

The appointment of Professor Helga Sanner at the University of Oslo marks both professional recognition and a clear strengthening of REMEDY's research on serious rheumatic diseases in children.

What happens when a researcher studying the risk of childhood arthritis gets to work closely with one of the world's most experienced environments within rheumatic diseases?

Through external funding, Hilde Ørbo had the opportunity to immerse herself in one of the world's strongest rheumatology research environments. For Ørbo, her stay abroad in Boston was both a professional breakthrough and a personal experience that she will take with her.

What gives patients with psoriatic arthritis the best possible treatment early in the disease? That is the question in NOR-SPRINT, a national clinical study led by Siri Lillegraven at Diakonhjemmet Hospital.

One of the world's leading experts in rheumatology and outcome assessment, Professor Désirée van der Heijde has served as a visiting professor at the REMEDY Center since 2024.

As a project manager in several projects on digital health, professor and physiotherapist Anne Therese Tveter is clear that digital solutions do not automatically lead to better treatment. For her, it is about further developing research that gives patients better conditions to make informed choices about their own health.

Interstitial lung disease (ILD) is one of the most serious complications of systemic rheumatic diseases. Often, clear symptoms are not experienced until significant lung damage has occurred. Now, research is underway to see if home-based digital monitoring can help detect and treat the disease earlier.

Treatment of serious autoimmune diseases has improved significantly in recent decades. However, there are patients who do not achieve lasting recovery, no matter how advanced the treatment is. This has created interest in CAR-T in rheumatology.